Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.

Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA; Children's Oncology Group.

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566.

2.

Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.

Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N.

Am J Clin Oncol. 1995 Apr;18(2):93-9.

PMID:
7900714
3.

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H.

J Clin Oncol. 2005 Mar 20;23(9):2004-11.

4.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE; Children's Oncology Group.

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095.

5.

Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.

Meyers PA, Chou AJ.

Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Review.

PMID:
24924182
6.

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.

Mori K, Ando K, Heymann D.

Expert Rev Anticancer Ther. 2008 Feb;8(2):151-9. doi: 10.1586/14737140.8.2.151. Review.

PMID:
18279055
7.

Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A.

Pediatr Blood Cancer. 2014 Feb;61(2):238-44. doi: 10.1002/pbc.24686. Epub 2013 Aug 31.

8.

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.

Kleinerman ES.

Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Review.

PMID:
7490249
9.
10.

Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.

Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N.

J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):181-93.

PMID:
7613644
11.

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP.

Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. Review.

PMID:
16529542
12.

Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Ando K, Mori K, Corradini N, Redini F, Heymann D.

Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129. Review.

13.

Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.

Kleinerman ES, Maeda M, Jaffe N.

Cancer Treat Res. 1993;62:101-7. Review.

PMID:
8096724
15.

Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.

Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, et al.

Clin Cancer Res. 1995 Dec;1(12):1595-601.

16.

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox LE, Keller ET, Obradovich J, et al.

J Drug Target. 1994;2(5):391-6.

PMID:
7704483
17.

Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).

Ferrari S, Meazza C, Palmerini E, Tamburini A, Fagioli F, Cozza R, Ferraresi V, Bisogno G, Mascarin M, Cefalo G, Manfrini M, Capanna R, Biagini R, Donati D, Picci P.

Tumori. 2014 Nov-Dec;100(6):612-9. doi: 10.1700/1778.19262.

PMID:
25688494
18.

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

Meyers PA.

Expert Rev Anticancer Ther. 2009 Aug;9(8):1035-49. doi: 10.1586/era.09.69. Review.

PMID:
19671023
19.

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup.

J Natl Cancer Inst. 2007 Jan 17;99(2):112-28.

20.

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.

Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N.

J Clin Oncol. 1992 Aug;10(8):1310-6.

PMID:
1634921
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk